If you have heard that SPRAVATO® is related to ketamine, you may be asking, “Is SPRAVATO federally legal?” The short answer is yes. SPRAVATO is federally legal in the United States when prescribed and administered according to federal requirements.
SPRAVATO contains esketamine, which is chemically related to ketamine. While that connection is sometimes confusing, SPRAVATO is an FDA-approved prescription medication with specific medical uses and safety requirements. Understanding that distinction can help you be more informed when considering whether treatment is right for you.
Yes, esketamine is classified as a Schedule III controlled substance under the federal Controlled Substances Act. Being a controlled substance does not make a medication illegal. Instead, it means federal regulations control how it can be prescribed, distributed, and administered because of its potential for misuse and abuse.
SPRAVATO received initial FDA approval in 2019 for adults with treatment-resistant depression. The approved indications have since expanded. Today, SPRAVATO can be used as a monotherapy or in conjunction with an oral antidepressant for adults with treatment-resistant depression.
It is also approved, when used with an oral antidepressant, for depressive symptoms in adults with major depressive disorder who are experiencing acute suicidal ideation or behavior.
Because SPRAVATO can cause serious side effects, you cannot pick up a prescription at your neighborhood pharmacy and administer the medication at home. You must receive treatment in a healthcare setting certified through the SPRAVATO Risk Evaluation and Mitigation Strategy (REMS) program.
During federally legal SPRAVATO treatment sessions, you administer the nasal spray under the supervision of a healthcare professional. We then monitor you for at least two hours.
This monitoring period is an important part of your treatment. SPRAVATO can cause:
You will also need to plan for someone to drive you home since you cannot drive or operate machinery until the next day following a restful sleep.
It is easy to see why the names SPRAVATO, esketamine, and ketamine are sometimes used interchangeably, but there are important differences.
SPRAVATO is the brand name for an FDA-approved esketamine nasal spray. Ketamine is also an FDA-approved medication, but its FDA-approved use is as an anesthetic rather than in psychiatric treatment. When ketamine is used to treat a psychiatric condition such as depression, that use is considered off-label.
Knowing which medication you are receiving and why it has been prescribed can help you have a more productive conversation with your provider about the potential benefits, risks, and alternatives.
Legitimate SPRAVATO treatment follows a structured process. Before treatment begins, we evaluate whether you are an appropriate candidate. If SPRAVATO is prescribed, treatment is provided in a REMS-certified healthcare setting, and you stay under medical supervision after each dose.
These requirements may sound restrictive, but they serve an important purpose. They allow you to receive an FDA-approved treatment while helping healthcare professionals manage the known risks.
If depression has continued despite previous treatments, you may be wondering whether SPRAVATO offers another option. The Grant Group provides SPRAVATO treatment for eligible patients as part of our psychiatric services.
The first step is determining whether this treatment fits your needs. We review your symptoms, medical history, previous depression treatments, and other relevant factors before recommending a treatment plan.
If you want to explore your treatment options and have questions, including whether SPRAVATO is federally legal, its safety, or what happens during treatment, contact The Grant Group to request an appointment. Getting clear information helps you make a more informed decision about what comes next.
